NACSTOP

From Wiki Journal Club
Jump to: navigation, search
Wong A. "The NACSTOP Trial: A Multicenter, Cluster-Controlled Trial of Early Cessation of Acetylcysteine in Acetaminophen Overdose". Hepatology. 2019. 69(2):774-784.
PubMedClinicalTrials.gov

Clinical Question

Bottom Line

Major Points

Guidelines

As of May 2019, no guidelines have been published that reflect the results of this trial.

Design

  • Multicenter, double-blind, parallel-group, randomized, controlled trial
  • N=
    • Intervention (n=)
    • Placebo (n=)
  • Setting:
  • Enrollment:
  • Mean follow-up:
  • Analysis:
  • Primary Outcome:

Population

Inclusion Criteria

Exclusion Criteria

  • pregnancy
  • acetaminophen modified-release ingestion, and
  • other supratherapeutic ingestions (i.e., unintentional ingestions of more than 10 g or more than 200 mg/kg over 24 hours, more than 6 g/day over 48 hours)

Baseline Characteristics

BLANK Group displayed

  • Demographics:
  • Physiologic parameters:
  • Anthropomorphics: Weight
  • Labs:
  • Site of infection

Interventions

Outcomes

Comparisons are BLANK therapy vs. BLANK therapy.

Primary Outcomes

Secondary Outcomes

Subgroup Analysis

Adverse Events

Criticisms

Funding

  • Australian National Health and Medical Research Council Postgraduate Scholarship (1114284)
  • the Morson Taylor Award, Australasian College for Emergency Medicine

Further Reading

≤ ≥